WVE News and Press, Wave Life Sciences Ltd. From 05/10/21

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and C...

CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and c...

uniQure has submitted data to the FDA that suggest that etranacogene dezaparvovec (AMT-061) is highly unlikely to be the cause of liver cancer in a patient in the pivotal trial. FTC review of the transaction with CSL Behring is ongoing and is projected to close during the second quart...

Shares of Wave Life Sciences (NASDAQ: WVE) are down 29% at 1:29 p.m. EDT after the company announced that WVE-120102 and WVE-120101, two of its drugs to treat Huntington's disease, failed to show an effect in early stage clinical trials. Huntington's disease is caused by differe...

Gainers: VirTra (VTSI) +83%.Color Star Technology (CSCW) +39%.Performant Financial (PFMT) +36%.VivoPower International (VVPR) +32%.Moxian (MOXC) +26%.Mannatech (MTEX) +23%.Novan (NOVN) +21%.Canaan (CAN) +20%.Lizhi (LIZI) +17%.17 Education & Technology (YQ) +17%.Losers: Elit...

Gainers: Novan (NOVN) +17%, ShockWave Medical (SWAV) +17%, Orphazyme (ORPH) +13%, Moleculin Biotech (MBRX) +14%, Annovis Bio (ANVS) +8%.Losers: Wave Life Sciences (WVE) -30%, Trxade (MEDS) -27%, Universe Pharmaceuticals (UPC)&#x...

Gainers: [[SEAC]] +30.3%. [[ABCL]] +13.7%. [[VSTM]] +9.7%. [[GIII]] +9.5%. [[RRR]] +8.8%.Losers: [[WVE]] -24.8%. [[SCPH]] -15.4%. [[PCVX]] -12%. [[UPC]] -9.5%. [[TDUP]] -6%. For further details see: VSTM, WVE, ABCL and SCPH among after-hours movers

Wave Life Sciences (WVE) has lost more than a quarter after announcing a halt to the clinical development of WVE-120102 and WVE-120101 in Huntington’s disease (“HD”).“mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120...

mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101 No observed change in wtHTT and NfL during trials Advancing Phase 1b/2a trial for WVE-003 (SNP3) program in HD; WVE-003 uses new PN backbone chemistry modifications, which...

Ionis Pharmaceuticals ([[IONS]] -22.5%) has lost almost a fifth after announcing that the partner Roche Holding ([[RHHBY]] -3.3%) has discontinued the dosing in the Phase III GENERATION HD1 study for Tominersen in manifest Huntington's disease (“HD”).An investigational...